TriSalus Life Sciences (TLSI) Net Income towards Common Stockholders (2021 - 2026)

TriSalus Life Sciences (TLSI) has 6 years of Net Income towards Common Stockholders data on file, last reported at $1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 113.88% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at -$58.5 million (down 92.95% YoY), and the FY2025 full-year result was -$69.7 million, down 109.7% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $1.5 million, up from -$9.8 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $1.9 million in Q2 2022 and bottomed at -$41.3 million in Q3 2025.
• The 5-year median for Net Income towards Common Stockholders is -$9.2 million (2023), against an average of -$11.6 million.
• Peak annual rise in Net Income towards Common Stockholders reached 2419.36% in 2022, while the deepest fall reached 4565.49% in 2022.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$25.4 million in 2022, then sank by 43.62% to -$36.4 million in 2023, then surged by 70.11% to -$10.9 million in 2024, then climbed by 10.45% to -$9.8 million in 2025, then soared by 115.78% to $1.5 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $1.5 million (Q1 2026), -$9.8 million (Q4 2025), and -$41.3 million (Q3 2025), per Business Quant data.

Peer Comparison